

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25573

Title: Exploring the role of molecular biomarkers as a potential weapon against gastric cancer

Reviewer's code: 03505688

Reviewer's country: Spain

Science editor: Ze-Mao Gong

Date sent for review: 2016-03-18 09:16

Date reviewed: 2016-03-29 17:52

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Comments on the manuscript : ESPS No: 25573 "Exploring the role of molecular biomarkers as a potential weapon against gastric cancer" by Matboli et al.,. General work focusing on molecular pathways of GC that can guide therapeutic management of the disease. A review on molecular biomarkers predicting treatment response (Genetic and epigenetic, protein). Present a summary of molecular aberrations as potential target for novel agents (Ramucirumab, Bevacizumab, multi-tyrosine kinase inhibitors, EGFR inhibition based agents, Pi3K/AKT/mTor inhibitors, Met inhibitors, immune checkpoints inhibitors and insulin like growth factor monoclonal antibody). Finally, they review future candidates such as Gatrokine1, HDAC inhibitors and long non-coding RNAs. Comments: -Title should state clearly that the report is a review. -Affiliations should not state author status, ex. Undergraduate student. -Although review is focused on the more adequate personalized treatments according to the altered molecular pathways in gastric cancer, some general recent articles could be also barely discussed, such as: - Cristescu et al., Nature Medicine, v21(5): 449-456, 2015 entitled: Molecular analysis of gastric cancer identifies subtypes associated with distinct



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

clinical outcomes - The Cancer Genome Atlas Research Network: nature, 513: 202-209, 2014 Minor:
-Some long English sentences should be revised and shortened. -Pag 5 "... these signature genetic studies..." may be improved to "these genetic signature studies..." -Check errors such as: "monotherapyor" (pag 13) that should read as "monotherapy" and "or"..... "trastuzumabtherapy" (pag 14) should be "trastuzumab" and "therapy"... I found several through the whole text - Check misspellings: pag 14: anatgonist, should be antagonist English should be revised thorough all text.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 25573

Title: Exploring the role of molecular biomarkers as a potential weapon against gastric cancer

Reviewer's code: 02537326

Reviewer's country: Japan

Science editor: Ze-Mao Gong

Date sent for review: 2016-03-18 09:16

Date reviewed: 2016-04-23 09:59

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors reviewed a role of biomarkers in gastric cancer. The manuscript is basically well written, however, the contents are a little bit different from the aim of this review. In the first part of the manuscript, the authors actually reviewed the biomarkers that may predict response or prognosis of the treatment, however, the latter part of the manuscript the authors just listed the results of clinical trials not mentioned about the biomarkers. In addition, most of the considerations are shallow and already published elsewhere. The authors should revise the manuscript following above mentioned comments.